GAMMA Investing
NVCT icon

GAMMA Investing’s Nuvectis Pharma NVCT Stock Holding History

GAMMA Investing’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$18.8K Buy
889
+400
+82% +$8.44K ﹤0.01% 2983
2026
Q2 		$8.99K Sell
489
-156
-24% -$1.75K ﹤0.01% 3265
2026
Q1 		$4.99K Buy
645
+474
+277% +$4.06K ﹤0.01% 3362
2025
Q4 		$1.29K Buy
171
+83
+94% +$541 ﹤0.01% 3725
2025
Q3 		$530 Buy
+88
New +$605 ﹤0.01% 3710
2024
Q2 		– Sell
-25
Closed -$205 – 3494
2024
Q1 		$205 Buy
+25
New +$213 ﹤0.01% 3226

Other funds holding NVCT

Iridian Asset Management
Iridian Asset Management Westport, Connecticut $275M AUM 37.66% 1-Year Est. Return
Baldwin Wealth Partners
Baldwin Wealth Partners Marion, Massachusetts $1.52B AUM 21.45% 1-Year Est. Return
J.M. Forbes & Co
J.M. Forbes & Co Boston, Massachusetts $1.33B AUM 21.14% 1-Year Est. Return
Sterling Capital Management
Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return
Essential Partners
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
Root Financial Partners
Root Financial Partners Encinitas, California $2.98B AUM 13.9% 1-Year Est. Return
True Wealth Design
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

GAMMA Investing's NVCT Position: Q3 2026 in Review

GAMMA Investing increased its Nuvectis Pharma (NVCT) stake by 82% in Q3 2026, buying an estimated $8.44K and bringing the position to 889 shares worth $18.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2983.

GAMMA Investing first reported a position in NVCT in Q1 2024 and has held it in 6 quarters since. 11 funds tracked by Wall St. Rank hold NVCT as of Q3 2026.

  • GAMMA Investing held 889 shares of Nuvectis Pharma worth $18.8K as of Q3 2026.
  • GAMMA Investing bought 400 Nuvectis Pharma shares in Q3 2026, an estimated $8.44K.
  • Nuvectis Pharma made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #2983 holding.
  • GAMMA Investing first reported a position in Nuvectis Pharma in Q1 2024 and has held it in 6 quarters since.
  • 11 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.